H Lundbeck A/S (HLUN-B) - Total Assets

Latest as of December 2025: Dkr54.01 Billion DKK ≈ $8.45 Billion USD

Based on the latest financial reports, H Lundbeck A/S (HLUN-B) holds total assets worth Dkr54.01 Billion DKK (≈ $8.45 Billion USD) as of December 2025. Total assets represent everything the company owns and controls, combining both current assets—like cash and cash equivalents, accounts receivable, and inventories—and non-current assets such as property, plant, equipment (PP&E), intangible assets, and long-term investments. Explore H Lundbeck A/S (HLUN-B) debt coverage ratio to assess how comfortably operating cash covers total debt obligations.

H Lundbeck A/S - Total Assets Trend (2004–2025)

This chart illustrates how H Lundbeck A/S's total assets have evolved over time, based on quarterly financial data. See H Lundbeck A/S shareholders equity for net asset value and shareholders' equity analysis.

H Lundbeck A/S - Asset Composition Analysis

Current Asset Composition (December 2025)

H Lundbeck A/S's total assets of Dkr54.01 Billion consist of 23.7% current assets and 76.3% non-current assets.

Asset Category Amount (DKK) % of Total Assets
Cash & Equivalents Dkr0.00 6.4%
Accounts Receivable Dkr4.55 Billion 8.4%
Inventory Dkr4.47 Billion 8.3%
Property, Plant & Equipment Dkr0.00 0.0%
Intangible Assets Dkr28.77 Billion 53.3%
Goodwill Dkr7.01 Billion 13.0%

Asset Composition Trend (2004–2025)

This chart illustrates how H Lundbeck A/S's asset composition has evolved over time. Understanding changes in asset allocation can provide insights into the company's strategic shifts, capital allocation priorities, and business focus evolution. For live market cap, price, and company overview, see H Lundbeck A/S (HLUN-B) total market value.

Key Asset Composition Facts

  • Current vs. Non-Current Assets: H Lundbeck A/S's current assets represent 23.7% of total assets in 2025, a decrease from 51.7% in 2004.
  • Cash Position: Cash and equivalents constituted 6.4% of total assets in 2025, down from 25.2% in 2004.
  • Tangible vs. Intangible: Intangible assets (including goodwill) make up 65.0% of total assets, an increase from 14.0% in 2004.
  • Asset Diversification: The largest asset category is intangible assets at 53.3% of total assets.

H Lundbeck A/S Competitors by Total Assets

Key competitors of H Lundbeck A/S based on total assets are shown below.

Company Country Total Assets
Takeda Pharmaceutical Company Limited
F:TKDA
Germany €15.41 Trillion
Shanghai Haoyuan Chemexpress Co. Ltd. A
SHG:688131
China CN¥6.49 Billion
Beijing New Oriental Star Petrochemical Engineering Co Ltd
SHE:002755
China CN¥4.44 Billion
Zhejiang Hisoar Pharmaceutical Co Ltd
SHE:002099
China CN¥7.28 Billion
Celltrion Pharm Inc
KQ:068760
Korea ₩745.80 Billion
Shanghai Yizhong Pharmaceutical Co Ltd
SHG:688091
China CN¥1.54 Billion
Heilongjiang ZBD Pharmaceutical Co Ltd
SHG:603567
China CN¥11.80 Billion
Zhejiang Anglikang Pharmaceutical Co Ltd Class A
SHE:002940
China CN¥3.12 Billion

H Lundbeck A/S - Liquidity and Working Capital Analysis

Liquidity ratios measure a company's ability to pay off its short-term debts as they come due, using the company's current or quick assets. Working capital represents the operational liquidity available.

Key Liquidity Metrics

Metric Current 1 Year Ago 5 Years Ago
Current Ratio 1.44 1.52 1.02
Quick Ratio 0.94 1.05 0.69
Cash Ratio 0.00 0.00 0.00
Working Capital Dkr3.93 Billion Dkr4.43 Billion Dkr143.00 Million

H Lundbeck A/S - Advanced Valuation Insights

This section examines the relationship between H Lundbeck A/S's asset base and its market valuation, helping to identify whether the company's assets are efficiently translated into market value.

Key Valuation Metrics

Current Price-to-Book Ratio 1.60
Latest Market Cap to Assets Ratio 0.10
Asset Growth Rate (YoY) -5.2%
Total Assets Dkr54.01 Billion
Market Capitalization $5.15 Billion USD

Valuation Analysis

Below Book Valuation: The market values H Lundbeck A/S's assets below their book value (0.10x), which may indicate investor concerns about asset quality or future growth.

Significant Asset Reduction: H Lundbeck A/S's assets decreased by 5.2% over the past year, potentially indicating divestiture, restructuring, or challenging business conditions.

Annual Total Assets for H Lundbeck A/S (2004–2025)

The table below shows the annual total assets of H Lundbeck A/S from 2004 to 2025.

Year Total Assets Change
2025-12-31 Dkr54.01 Billion
≈ $8.45 Billion
-5.20%
2024-12-31 Dkr56.98 Billion
≈ $8.91 Billion
+52.31%
2023-12-31 Dkr37.41 Billion
≈ $5.85 Billion
-0.12%
2022-12-31 Dkr37.45 Billion
≈ $5.86 Billion
+8.08%
2021-12-31 Dkr34.65 Billion
≈ $5.42 Billion
-3.82%
2020-12-31 Dkr36.03 Billion
≈ $5.64 Billion
+0.76%
2019-12-31 Dkr35.76 Billion
≈ $5.59 Billion
+55.39%
2018-12-31 Dkr23.01 Billion
≈ $3.60 Billion
+16.48%
2017-12-31 Dkr19.76 Billion
≈ $3.09 Billion
-2.25%
2016-12-31 Dkr20.21 Billion
≈ $3.16 Billion
-5.23%
2015-12-31 Dkr21.32 Billion
≈ $3.34 Billion
-16.82%
2014-12-31 Dkr25.64 Billion
≈ $4.01 Billion
+8.41%
2013-12-31 Dkr23.65 Billion
≈ $3.70 Billion
+9.67%
2012-12-31 Dkr21.56 Billion
≈ $3.37 Billion
+5.01%
2011-12-31 Dkr20.53 Billion
≈ $3.21 Billion
+14.05%
2010-12-31 Dkr18.00 Billion
≈ $2.82 Billion
+5.13%
2009-12-31 Dkr17.13 Billion
≈ $2.68 Billion
+35.86%
2008-12-31 Dkr12.61 Billion
≈ $1.97 Billion
+2.28%
2007-12-31 Dkr12.33 Billion
≈ $1.93 Billion
+5.98%
2006-12-31 Dkr11.63 Billion
≈ $1.82 Billion
+0.02%
2005-12-31 Dkr11.63 Billion
≈ $1.82 Billion
+1.04%
2004-12-31 Dkr11.51 Billion
≈ $1.80 Billion
--

About H Lundbeck A/S

CO:HLUN-B Denmark Drug Manufacturers - Specialty & Generic
Market Cap
$5.15 Billion
Dkr32.91 Billion DKK
Market Cap Rank
#3458 Global
#22 in Denmark
Share Price
Dkr41.50
Change (1 day)
-1.14%
52-Week Range
Dkr33.78 - Dkr47.34
All Time High
Dkr90.49
About

H. Lundbeck A/S engages in the research, development, manufacturing, and commercializing pharmaceuticals for the treatment of psychiatric and neurological disorders in Europe, United States, and internationally. The company offers Abilify Maintena/ Abilify Asimtufii for schizophrenia and bipolar I disorder in adults; Brintellix/Trintellix to treat depressive disorders; Rexulti/Rxulti to treat maj… Read more